Proactive Investors - Run By Investors For Investors

ANGLE device offers breakthrough in prostate cancer care

The team at the Bart's Cancer Institute at Queen Mary University will present their full findings at the National Cancer Research Institute next week.
ANGLE device offers breakthrough in prostate cancer care
The company's Parsortix device offers a non-invasive means of detecting prostate cancer.

ANGLE PLC (LON:AGL, OTCQX:ANPCY) has welcomed new research that potentially supports the use of the company’s breakthrough cancer detection system as an alternative to biopsies in men with suspected prostate cancer.

The team at the Bart's Cancer Institute at Queen Mary University will present their full findings at the National Cancer Research Institute next week.

What they found was ANGLE’s Parsortix device was able to capture a very specific subset of circulating tumour cells from prostate cancer patient blood samples.

These cells, which cannot be captured by traditional systems, are linked to the spread of the disease.

It means Parsortix could potentially be used gauge at what stage and how severe the prostate cancer is.

Andrew Newland, chief executive and the med-tech company’s founder, said: "This is a significant milestone, which further supports the adoption of Parsortix as a non-invasive alternative to the biopsy of prostate tissue.”

Currently the removal of tissue is standard for men with suspected prostate cancer - yet 75% to 80% of them do not have the disease. It means they risk serious complications.

“Aside from being non-invasive, Parsortix has the potential to provide the additional staging information to allow physicians to determine which patients require treatment and to provide active monitoring for all prostate cancer patients,” said Newland. 

“We look forward to our continued work with Barts to progress the use of Parsortix in prostate cancer."

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
man coughing
November 09 2018
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use